| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| ln Vitro |
CPD-002 (0-64 μM, 24-48 h) is cytotoxic to HUVEC and MH7A cells in a dose-dependent manner [1]. CPD-002 (0-8 μM, 24 h) inhibits VEGF-induced HUVEC cell migration and invasion by suppressing F-actin expression and chemotactic response to chemoattractants released by MH7A cells [1]. CPD-002 (0-8 μM) exerts anti-inflammatory activity by inhibiting inflammatory mediators such as TNF-α, IL-1β, IL-6, IL-8, MMP2, and MMP9, thereby inhibiting synovial angiogenesis[1]. CPD-002 (0-8 μM, 9 days) inhibits HUVEC tube formation and aortic ring sprout formation in an isolated rat aortic ring assay [1].
|
|---|---|
| ln Vivo |
CPD-002 (15-60 mg/kg, intraperitoneally, once daily for 14 days) exhibits anti-arthritic and anti-angiogenic activities in an adjuvant-induced arthritis rat model [1].
|
| Cell Assay |
Cell Viability Assay[1]
Cell Types: HUVECs and MH7A Tested Tested Concentrations: 0-64 μM Incubation Duration: 24-48 h Experimental Results: Inhibited cell viability in a dose-dependent manner. Cell Migration Assay [1] Cell Types: HUVECs Tested Tested Concentrations: 0-8 μM Incubation Duration: 24 h Experimental Results: Inhibited HUVECs migration in a dose-dependent manner. |
| Animal Protocol |
Animal/Disease Models: adjuvant-induced arthritis (AIA) Sprague Dawley rats models[1]
Doses: 15-60 mg/kg Route of Administration: i.p., once daily for 14 days Experimental Results: Ameliorated paw swelling, joint damage, and synovial angiogenesis. |
| References |
| Molecular Formula |
C17H16N4O2S
|
|---|---|
| Molecular Weight |
340.40
|
| CAS # |
2617376-08-4
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.9377 mL | 14.6886 mL | 29.3772 mL | |
| 5 mM | 0.5875 mL | 2.9377 mL | 5.8754 mL | |
| 10 mM | 0.2938 mL | 1.4689 mL | 2.9377 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
